Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 66

1.

Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Torimoto K, Miyake M, Anai S, Fujii T, Hasegawa M, Fujimoto K.

J Contemp Brachytherapy. 2019 Oct;11(5):409-416. doi: 10.5114/jcb.2019.88142. Epub 2019 Oct 30.

2.

Prostate-specific antigen bounce after 125I-brachytherapy for prostate cancer is a favorable prognosticator in patients who are biochemical recurrence-free at 4 years and correlates with testosterone.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Morizawa Y, Hori S, Owari T, Fujii T, Yamaki K, Hasegawa M, Fujimoto K.

Jpn J Clin Oncol. 2019 Oct 28. pii: hyz136. doi: 10.1093/jjco/hyz136. [Epub ahead of print]

PMID:
31665354
3.

A Potential Application of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Combined with Photodynamic Diagnosis for the Detection of Bladder Carcinoma in Situ: Toward the Future 'MRI-PDD Fusion TURBT'.

Miyake M, Maesaka F, Marugami N, Miyamoto T, Nakai Y, Ohnishi S, Gotoh D, Owari T, Hori S, Morizawa Y, Itami Y, Inoue T, Anai S, Torimoto K, Fujii T, Shimada K, Tanaka N, Fujimoto K.

Diagnostics (Basel). 2019 Sep 4;9(3). pii: E112. doi: 10.3390/diagnostics9030112.

4.

Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.

Miyake M, Hori S, Ohnishi S, Toritsuka M, Fujii T, Shimizu T, Owari T, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Anai S, Torimoto K, Tanaka N, Fujimoto K.

Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.

5.

The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions.

Miyake M, Tanaka N, Asakawa I, Owari T, Hori S, Morizawa Y, Nakai Y, Inoue T, Anai S, Torimoto K, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Prostate Int. 2019 Jun;7(2):47-53. doi: 10.1016/j.prnil.2018.04.005. Epub 2018 May 5.

6.

Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.

Miyake M, Hori S, Ohnishi S, Owari T, Iida K, Ohnishi K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujii T, Tanaka N, Fujimoto K.

Diseases. 2019 Jun 18;7(2). pii: E44. doi: 10.3390/diseases7020044.

7.

Comparison of cancer detection rates by transrectal prostate biopsy for prostate cancer using two different nomograms based on patient's age and prostate volume.

Hori S, Tanaka N, Nakai Y, Morizawa Y, Tatsumi Y, Miyake M, Anai S, Fujii T, Konishi N, Nakagawa Y, Hirao S, Fujimoto K.

Res Rep Urol. 2019 Mar 19;11:61-68. doi: 10.2147/RRU.S193933. eCollection 2019.

8.

Mycoplasma genitalium Infection and Chronic Inflammation in Human Prostate Cancer: Detection Using Prostatectomy and Needle Biopsy Specimens.

Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, Furuya H, Rosser CJ, Fujimoto K.

Cells. 2019 Mar 2;8(3). pii: E212. doi: 10.3390/cells8030212.

9.

Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel KIF5B-ALK Fusion Oncokinase.

Shimizu N, Akashi Y, Fujii T, Shiono H, Yane K, Kitahara T, Ohta Y, Kakudo K, Wakasa T.

Anticancer Res. 2019 Jan;39(1):413-420. doi: 10.21873/anticanres.13127.

PMID:
30591488
10.

Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.

Nakai Y, Tanaka N, Asakawa I, Anai S, Miyake M, Hori S, Morizawa Y, Tatsumi Y, Hasegawa M, Fujii T, Fujimoto K.

J Radiat Res. 2019 Mar 1;60(2):270-280. doi: 10.1093/jrr/rry101.

11.

Changes in lower urinary tract symptoms after iodine-125 brachytherapy for prostate cancer.

Onishi K, Tanaka N, Miyake M, Nakai Y, Anai S, Torimoto K, Yamaki K, Asakawa I, Hasegawa M, Fujii T, Konishi N, Fujimoto K.

Clin Transl Radiat Oncol. 2018 Nov 17;14:51-58. doi: 10.1016/j.ctro.2018.11.001. eCollection 2019 Jan.

12.

Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model.

Miyake M, Tanaka N, Hori S, Ohnishi S, Takahashi H, Fujii T, Owari T, Ohnishi K, Iida K, Morizawa Y, Gotoh D, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Aoki K, Fujimoto K.

Prostate. 2019 Mar;79(4):340-351. doi: 10.1002/pros.23740. Epub 2018 Nov 18.

PMID:
30450646
13.

Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer.

Nakai Y, Tanaka N, Anai S, Miyake M, Asakawa I, Morizawa Y, Hori S, Torimoto K, Fujii T, Hasegawa M, Fujimoto K.

Res Rep Urol. 2018 Oct 23;10:169-180. doi: 10.2147/RRU.S168651. eCollection 2018.

14.

Colony-stimulating factors detected in tumor cells and voided urine are potential prognostic markers for patients with muscle-invasive bladder cancer undergoing radical cystectomy.

Morizawa Y, Miyake M, Shimada K, Hori S, Tatsumi Y, Nakai Y, Tanaka N, Fujii T, Fujimoto K.

Res Rep Urol. 2018 Sep 21;10:103-111. doi: 10.2147/RRU.S166497. eCollection 2018.

15.

NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.

Morita K, Fujii T, Itami H, Uchiyama T, Nakai T, Hatakeyama K, Sugimoto A, Miyake M, Nakai Y, Tanaka N, Shimada K, Yamazaki M, Fujimoto K, Ohbayashi C.

Cancers (Basel). 2018 Sep 21;10(10). pii: E347. doi: 10.3390/cancers10100347.

16.

Immunohistochemical Reappraisal Regarding the Frequency of Primary Salivary Gland Follicular Lymphoma.

Itami H, Nakamine H, Takeda M, Nakai T, Myojin T, Matsuoka M, Sasaki S, Uchiyama T, Morita K, Fujii T, Hatakeyama K, Ohbayashi C.

Int J Surg Pathol. 2019 Feb;27(1):48-54. doi: 10.1177/1066896918784349. Epub 2018 Jul 4.

PMID:
29972093
17.

Real-time ultrasound-guided infraorbital nerve block to treat trigeminal neuralgia using a high concentration of tetracaine dissolved in bupivacaine.

Takechi K, Konishi A, Kikuchi K, Fujioka S, Fujii T, Yorozuya T, Kuzume K, Nagaro T.

Scand J Pain. 2015 Jan 1;6(1):51-54. doi: 10.1016/j.sjpain.2014.10.003.

PMID:
29911581
18.

MicroRNAs in Smoking-Related Carcinogenesis: Biomarkers, Functions, and Therapy.

Fujii T, Shimada K, Nakai T, Ohbayashi C.

J Clin Med. 2018 May 1;7(5). pii: E98. doi: 10.3390/jcm7050098. Review.

19.

K-ras mutation analysis of residual liquid-based cytology specimens from endoscopic ultrasound-guided fine needle aspiration improves cell block diagnosis of pancreatic ductal adenocarcinoma.

Sekita-Hatakeyama Y, Nishikawa T, Takeuchi M, Morita K, Takeda M, Hatakeyama K, Nakai T, Uchiyama T, Itami H, Fujii T, Mitoro A, Sho M, Ohbayashi C.

PLoS One. 2018 Mar 1;13(3):e0193692. doi: 10.1371/journal.pone.0193692. eCollection 2018.

20.

Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor.

Tanaka N, Torimoto K, Asakawa I, Miyake M, Anai S, Nakai Y, Fujii T, Hasegawa M, Fujimoto K.

Brachytherapy. 2018 May - Jun;17(3):537-543. doi: 10.1016/j.brachy.2017.12.004. Epub 2018 May 7.

PMID:
29402711

Supplemental Content

Loading ...
Support Center